Reality Check on Glaucoma
Market access for glaucoma treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 60% of the lives under commercial formularies are covered without utilization management restrictions
- Class Trends: In March 2020, the FDA approved Allergan plc’s Durysta (bimatoprost
implant) 10 mcg to treat open-angle glaucoma or ocular hypertension. This is the first intracameral biodegradable sustained-release implant for the indication
- Key Findings: With various generics available within this therapeutic class, contracting is a critical component for branded agents. Formulary coverage is extensive, with generics available at the lowest copay tier and preferred agents in the formulary brand tier
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.